Cargando…

New Therapeutic Options for Advanced Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC), one of the most common lethal diseases in the world, has a 5-year survival rate of only 7%. Hepatocellular carcinoma has no symptoms in the early stage but obvious symptoms in the late stage, leading to delayed diagnosis and reduced treatment efficacy. In recent years...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yu-Shui, Liu, Ji-Bin, Wu, Ting-Miao, Fu, Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791453/
https://www.ncbi.nlm.nih.gov/pubmed/32799550
http://dx.doi.org/10.1177/1073274820945975
_version_ 1783633607933296640
author Ma, Yu-Shui
Liu, Ji-Bin
Wu, Ting-Miao
Fu, Da
author_facet Ma, Yu-Shui
Liu, Ji-Bin
Wu, Ting-Miao
Fu, Da
author_sort Ma, Yu-Shui
collection PubMed
description Hepatocellular carcinoma (HCC), one of the most common lethal diseases in the world, has a 5-year survival rate of only 7%. Hepatocellular carcinoma has no symptoms in the early stage but obvious symptoms in the late stage, leading to delayed diagnosis and reduced treatment efficacy. In recent years, as the scope of HCC research has increased in depth, the clinical development and application of molecular targeted drugs and immunotherapy drugs have brought new breakthroughs in HCC treatment. Targeted therapy drugs for HCC have high specificity, allowing them to selectively kill tumor cells and minimize damage to normal tissues. At present, these targeted drugs are mainly classified into 3 categories: small molecule targeted drugs, HCC antigen-specific targeted drugs, and immune checkpoint targeted drugs. This article reviews the latest research progress on the targeted drugs for HCC.
format Online
Article
Text
id pubmed-7791453
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77914532021-01-15 New Therapeutic Options for Advanced Hepatocellular Carcinoma Ma, Yu-Shui Liu, Ji-Bin Wu, Ting-Miao Fu, Da Cancer Control Review Hepatocellular carcinoma (HCC), one of the most common lethal diseases in the world, has a 5-year survival rate of only 7%. Hepatocellular carcinoma has no symptoms in the early stage but obvious symptoms in the late stage, leading to delayed diagnosis and reduced treatment efficacy. In recent years, as the scope of HCC research has increased in depth, the clinical development and application of molecular targeted drugs and immunotherapy drugs have brought new breakthroughs in HCC treatment. Targeted therapy drugs for HCC have high specificity, allowing them to selectively kill tumor cells and minimize damage to normal tissues. At present, these targeted drugs are mainly classified into 3 categories: small molecule targeted drugs, HCC antigen-specific targeted drugs, and immune checkpoint targeted drugs. This article reviews the latest research progress on the targeted drugs for HCC. SAGE Publications 2020-08-17 /pmc/articles/PMC7791453/ /pubmed/32799550 http://dx.doi.org/10.1177/1073274820945975 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Ma, Yu-Shui
Liu, Ji-Bin
Wu, Ting-Miao
Fu, Da
New Therapeutic Options for Advanced Hepatocellular Carcinoma
title New Therapeutic Options for Advanced Hepatocellular Carcinoma
title_full New Therapeutic Options for Advanced Hepatocellular Carcinoma
title_fullStr New Therapeutic Options for Advanced Hepatocellular Carcinoma
title_full_unstemmed New Therapeutic Options for Advanced Hepatocellular Carcinoma
title_short New Therapeutic Options for Advanced Hepatocellular Carcinoma
title_sort new therapeutic options for advanced hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791453/
https://www.ncbi.nlm.nih.gov/pubmed/32799550
http://dx.doi.org/10.1177/1073274820945975
work_keys_str_mv AT mayushui newtherapeuticoptionsforadvancedhepatocellularcarcinoma
AT liujibin newtherapeuticoptionsforadvancedhepatocellularcarcinoma
AT wutingmiao newtherapeuticoptionsforadvancedhepatocellularcarcinoma
AT fuda newtherapeuticoptionsforadvancedhepatocellularcarcinoma